Interaction of receptors for prostaglandin E1/prostacyclin and insulin in human erythrocytes and platelets.
Prostaglandin E1/I2 and insulin receptors of human erythrocyte and platelet are capable of modulating each other's activity. This modulation of the receptor activity and number in one system by a second receptor system in human platelet and erythrocyte seems to be beneficial. Insulin increases the PGE1 binding to platelets and thereby enhances the platelet antiaggregatory action of prostaglandin by increasing cyclic AMP levels. Similarly, PGE1 increases insulin binding to human erythrocyte, and thereby reduces the optimum concentration of insulin for a maximal reduction in membrane microviscosity. During ischemia the reduced response of platelets to the inhibitory effect of PGE1 or PGI2 relates to the impaired PGE1/I2 receptor activity. Treatment of these platelets with insulin at physiological concentrations can normalise the PGE1/I2 receptor activity. This review focuses on the relationship between the two receptor systems in human blood cells.
Dutta-Roy
A K
AK
Receptor Research Lab, Rowett Research Institute, Bucksburn, Aberdeen, Scotland, U.K.
Kahn
N N
NN
Sinha
A K
AK
D000527:Alprostadil / Q000097:blood; D001792:Blood Platelets / Q000378:metabolism*; D011464:Epoprostenol / Q000097:blood; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D011972:Receptor, Insulin / Q000097:blood*; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000097:blood*; D018078:Receptors, Prostaglandin E
D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D018078:Receptors, Prostaglandin E; D011464:Epoprostenol; D011972:Receptor, Insulin; D000527:Alprostadil